Ovarian Cancer

Research at TRI focussed on improving detection, diagnosis and treatment of ovarian cancer includes:

A non-invasive test to triage patients before surgery - using MR technology: Researchers and clinicians at TRI, Princess Alexandra (PA) Hospital and the Mater Hospital in Brisbane have teamed up to undertake a clinical trial of a non-invasive test to determine whether suspicious ovarian masses are benign or cancerous prior to surgery. Led by Prof Carolyn Mountford, CEO and Director of Research at TRI, the team is using a technique called magnetic resonance (MR) spectroscopy as a non-invasive means of evaluating tissue chemistry. Using this technique, they can also determine whether it is a low or high grade tumour, and whether it has spread beyond the ovary. This technology is currently in clinical trials, to automate and speed up the diagnostic process for patients with suspicious ovarian lesions. Read more.

Using radio-labelled antibodies to improve detection of location and extent of tumours: Mater Research Prof John Hooper is developing a novel PET imaging agent to improve treatment of ovarian cancer. It involves use of a radio-labelled antibody to help visualise the location and extent of ovarian cancer via PET imaging. Read more

Kallikrein proteases and ovarian cancer: QUT Prof Judith Clements and her team are investigating the functional role of kallikrein proteases in ovarian cancer, and whether genetic changes (single nucleotide polymorphisms (SNPs)) in the Kallikrein genes that may be predictors of ovarian cancer. Read more




Key Researchers
Carolyn Mountford
John Hooper
Judith Clements
TRI researchers have received vital funding from the Australian Government to trial a new diagnostic for epithelial ovarian cancer (EOC), the first study of its kind in humans. Mater Research...Read more
Australian scientists are ready to trial a new ‘precision-medicine’ agent designed to deliver imaging agents and anti-cancer drugs to ovarian and pancreatic cancers in patients with...Read more
Scientists from Mater Research – The University of Queensland, have discovered they can overcome chemotherapy resistance in an ovarian cancer subtype by using low doses of a drug which slows...Read more
Ovarian mass - cancer or benign? A non-invasive test to triage patients before surgery Researchers and clinicians at Translational Research Institute (TRI), Princess Alexandra (PA) Hospital and the...Read more
Over $5.9 million in NHMRC funding awarded to TRI-based researchers for 2019 In the latest round of NHMRC funding announced this month, TRI-based researchers from UQ, QUT and Mater-UQ have secured...Read more
Increasing the visibility of ovarian cancer Source: Mater Research News, Tuesday 14 August In 2018, more than 1,600 Australian women are estimated to be diagnosed with ovarian cancer. Most of these...Read more
Hope in the fight against ovarian cancer It's Ovarian Cancer Awareness month throughout March and QUT IHBI researchers have some exciting new research to share with the world. Queensland...Read more